An innovative platform and smartphone app to deliver tailored interventions and facilitate completed referrals related to substance use.

一个创新的平台和智能手机应用程序，可提供量身定制的干预措施并促进完成与药物使用相关的转介。

• 批准号: 9896540
• 负责人: Hans Morefield
• 金额: $ 18.47万
• 依托单位: CHESS MOBILE HEALTH, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9896540
• 关键词: Accident and Emergency department; Address; Adherence; Alcohol consumption; Alcohol or Other Drugs use; Behavior Therapy; Caring; Cellular Phone; Clinical; Computers; Data; Destinations; Disease; Drug usage; Elements; Funding; Goals; Health; Health Personnel; Individual; Intervention; Knowledge; Mind; Modification; Monitor; National Institute of Drug Abuse; Participant; Patient Care; Patient Noncompliance; Patients; Pharmaceutical Preparations; Phase; Primary Health Care; Provider; Randomized; Randomized Clinical Trials; Recommendation; Recovery; Research; Risk; Screening Result; Screening procedure; Secure; Self Management; Small Business Innovation Research Grant; Substance Use Disorder; Substance abuse problem; Technology; Testing; Validation; Work; base; care providers; compliance behavior; design; digital; efficacy study; efficacy testing; follow-up; health information technology; improved; innovation; medical specialties; outreach; patient engagement; personalized intervention; primary care setting; programs; prototype; reduced substance use; response; satisfaction; screening, brief intervention, referral, and treatment; smartphone Application; substance abuse treatment; success; tool; trend; usability; willingness

Abstract The goal of this fast-track SBIR proposal is to increase patient adherence to SBIRT-related recommendations given to patients by a primary care provider (PCP). The success of SBIRT (Screening, Brief Intervention, and Referral to Treatment) in the primary care setting has been inconsistent in terms of patients following through on treatment referral recommendations, with averages as low as 10%. For a variety of reasons, many patients, irrespective of their specific disease, do not adhere well to clinical recommendations. One way to improve adherence has been to personalize the recommendations for each individual’s needs, especially using digital technology, such as apps. The aim of NIDA to develop a sophisticated smart phone based tool for improving patient follow up to SBIRT recommendations is therefore well justified. CHESS Health has already developed an automated digital tool (eIntervention) with key elements requested by this RFA. eIntervention is designed to encourage patient adherence to PCP recommendations following SBIRT. Using a variety of the RFA required functionalities, eIntervention is designed to facilitate and motivate each patient to enter treatment, once that patient has been identified by SBIRT as having a substance use disorder (SUD) or as being at risk of such. eIntervention is commercially available and was developed in response to customer requests. However, eIntervention does not contain all of the functionalities requested by NIDA in this RFA and we do not have data to validate efficacy. Such validation is important for supporting wide spread dissemination. We propose to enhance our existing eIntervention solution with new functionalities that address the requirements set forth in this RFA and carry out a randomized study of efficacy. In Phase I, our Specific Aim is to evaluate feasibility of our program for improving adherence to SBIRT recommendations to patients from PCPs. This Specific Aim will be accomplished in two Tasks: Task 1: Add functionality to our prototype that address most requirements outlined in the RFA. Task 2: Demonstrate acceptability, feasibility, and preliminary efficacy of the prototype eIntervention in improving patient linkage to and engagement in indicated follow-up specialty SUD care. If shown to be feasible, in Phase II, our Specific Aim is to evaluate a near commercial quality product that contains all of the features required by the RFA. The Specific Aim will be accomplished in two Tasks: Task 1: Modifications to the program (months 1-3). Task 2: The randomized clinical trial to test efficacy of SBIRT/eIntervention compared to SBIRT/TAU. Criteria for Success: We aim to double the current rate of follow-up specialty SUD care (e.g. go from ~17% to an achieved rate of ~35%), a highly impactful effect. All patients, including those identified as at risk, must show a reduction in substance use. Patients and PCPs must rank the program with an average of 3.5 on a five-point Likert scale for usability, satisfaction, and willingness to use with the program again.

抽象的 这个快速曲目SBIR提案的目的是增加患者遵守与SBIRT相关建议的依从性 由初级保健提供者（PCP）给予患者。 Sbirt的成功（筛查，简短干预和 在初级保健环境中转介治疗）在跟随患者的情况下是不一致的 在治疗推荐建议下，平均值低至10％。由于多种原因，许多患者， 无论其特定疾病如何，都不符合临床建议。改进的一种方法 依从性是为每个人的需求个性化建议，尤其是使用数字 技术，例如应用程序。 NIDA开发基于精致的智能手机工具的目的 因此，患者跟进SBIRT建议是有道理的。 国际象棋健康已经开发了一种自动数字工具（Eintervention），并要求关键要素 通过这个RFA。 Eintervention旨在鼓励患者遵守PCP建议。 SBIRT。使用各种RFA所需的功能，旨在促进和激励 每个患者进入治疗，一旦Sbirt将患者识别为具有药物的使用 障碍（SUD）或有这种风险。 eintervention是在商业上可用的，并且是在 对客户请求的回应。但是，电子介入不包含所有要求的功能 NIDA在此RFA中，我们没有数据来验证效率。这种验证对于支持广泛很重要 传播传播。我们建议通过新功能来增强现有的电子介入解决方案 解决此RFA中规定的要求，并对效率进行随机研究。 在第一阶段，我们的具体目的是评估我们计划的可行性，以提高依从性 向来自PCP的患者提出建议。这个具体目标将在两个任务中完成： 任务1：将功能添加到我们的原型，以解决RFA中概述的大多数要求。 任务2：证明原型介入的可接受性，可行性和初步效率 改善患者与指定的随访专业泡沫护理的联系并参与。 如果证明是可行的，那么在第二阶段中，我们的具体目的是评估近乎商业质量的产品 包含RFA所需的所有功能。具体目标将在两个任务中完成： 任务1：对程序的修改（1-3个月）。 任务2：与SBIRT/TAU相比，测试SBIRT/Eintervention效率的随机临床试验。 成功标准：我们的目标是将当前的后续专业肥皂水护理率翻了一番（例如 达到〜35％的速率），这是一种高度影响的效果。所有患者，包括被确定为风险的患者，都必须 显示物质使用的减少。患者和PCP必须平均以3.5在A上排名 五点李克特量表，可用性，满意度和愿意再次使用该程序。